Sanofi-B (02257.HK) announced that it has completed the IND preparation phase study of the target lipid C3 (ApoC3) siRNA therapeutic drug STP125G, which is the second candidate drug based on its proprietary GalAhead mxRNA technology. The safety and efficacy results of non-human primate (NHP) studies strongly support the application of IND to the US FDA to initiate phase I clinical trials of STP125G for cardiovascular disease indications.
The company cannot guarantee that the STP125G drug will ultimately be successfully launched.